Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $11.14.

Several equities analysts have commented on ANTH shares. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. ValuEngine downgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.25 price target on shares of Anthera Pharmaceuticals in a report on Monday, May 15th.

Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its holdings in Anthera Pharmaceuticals by 1,376.1% during the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 335,595 shares during the period. UBS Group AG boosted its holdings in Anthera Pharmaceuticals by 9.9% during the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 33,901 shares during the period. Finally, Sabby Management LLC boosted its holdings in Anthera Pharmaceuticals by 1,809.7% during the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after acquiring an additional 1,665,655 shares during the period. Institutional investors own 27.26% of the company’s stock.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded down 6.25% on Wednesday, hitting $1.50. The company’s stock had a trading volume of 440,349 shares. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $27.36. The stock’s 50 day moving average price is $1.40 and its 200 day moving average price is $1.22. The stock’s market capitalization is $16.36 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. On average, analysts forecast that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Anthera Pharmaceuticals, Inc. (ANTH) Receives $11.14 Average Price Target from Analysts” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/04/anthera-pharmaceuticals-inc-anth-receives-11-14-average-price-target-from-analysts.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.